CClinicalTrials.gg
CompletedNCT02933918Updated Nov 18, 2023

Safety of Intranasal Irrigation Probiotics in Healthy Volunteers

An interventional study of Probiotics in Sinusitis, sponsored by Probionase Therapies Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Probionase Therapies Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Chronic rhinosinusitis (CRS) is one of the most common chronic diseases, affecting the quality of life of patients who suffer. Despite medical and surgical treatments available, there are a significant number of people suffering from CRS refractory to these standard treatments.

A preliminary clinical trial conducted at CHUM Hôtel-Dieu, has allowed us to evaluate the therapeutic potential of intranasal irrigation of probiotics in patients with CRS. This treatment administered twice daily for 14 days was well tolerated and resulted in improved chronic rhinosinusitis symptoms.

Prior to deployment on a larger scale, the safety of this therapy must be confirmed in a healthy population, free of sinus disease. Therefore, this study aims to assess the safety of the use of probiotic intranasal irrigation in healthy volunteers.

Read the detailed description

If the participant (healthy volunteer) agrees to participate in the study, and after signing the information consent form, her/his participation in this project will consist to receive the experimental treatment of probiotics, to come to four (4) medical assessment visits at CHUM, over a period of time of four (4) weeks, and answer to one (1) phone call.

This study will include five (5) periods :

  1. Determination of eligibility period (Day 0)
  2. Saline irrigation period (Day 0 to Day 7)
  3. Elimination of saline period (Day 8 to Day 14)
  4. Probiotic treatment period (Day 15 to Day 21)
  5. Telephone follow-up period (Day 22 to Day 28)
02

Conditions studied

  • Sinusitis

Browse trials for

Keywords

  • Probiotics
  • Nasal Irrigation
  • Healthy Volunteers
03

In context

Sinusitis

415 studies on the registry are indexed under Sinusitis; 46 are open to participants now.

This study's enrollment of 36 is below the median of 60 across 313 interventional studies indexed under Sinusitis.

Browse Sinusitis studies →

Lead sponsor

This is the only study on the registry with Probionase Therapies Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Men and women aged 18 and older.
  • Participant in general good health.
  • Absence of nasal and ear signs or symptoms.

Exclusion criteria

Exclusion Criteria:

  • Participant suffering from acute rhinosinusitis, chronic rhinosinusitis, symptomatic allergic rhinitis, or other sinus disease.
  • Participant with diseases of the middle ear causing impairment of the eardrum or middle ear, or have had surgery of the middle ear previously, except myringotomy with insertion tube.
  • Primary or acquired immunodeficiencies documented.
  • Antibiotic intake within 30 days before enrollment.
  • Unable to do nasal rinse.
  • Pregnant woman.
  • Smell score from UPSIT-40 under normal smell threshold (\<34).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Probiotics

    Other: Probiotics

Interventions

  • OtherProbiotics

    Safety of nasal irrigation with probiotics in healthy volunteers

06

What researchers measure

Primary outcomes

  1. Change in sense of smell using the "University of Pennsylvania smell identification test (UPSIT-40)"

    A smell test will be conducted using "scratch and sniff fragrance strips" (UPSIT-40), where 40 odors are presented. The participant must choose one of four choices for each odor, even if she/he is unable to identify the smell.

    Time frame: Change from baseline sense of smell at Day 7and Day 14

Secondary outcomes

  1. Change in sino-nasal symptomatology using questionnaire

    This questionnaire evaluates 5 items (nasal congestion, facial pain, headache, need to blow nose, post-nasal drip) on 0-3 scale (0= none; 1=mild; 2=moderate; 3= severe).

    Time frame: Change from baseline sino-nasal symptomatology at Day 7, Day 14 and Day 21

  2. Change in Eustachian tube symptomatology using a questionnaire of Eustachian Tube Dysfunction (ETDQ-7)

    Using a questionnaire of Eustachian Tube Dysfunction (ETDQ-7).

    Time frame: Change from baseline Eustachian tube symptomatology at Day 7, Day 14 and Day 21

  3. Change in ear examination

    Time frame: Change from baseline ear examination at Day 7 and Day 14

  4. Change in anterior rhinoscopy

    Time frame: Change from baseline anterior rhinoscopy at Day 7 and Day 14

Other outcomes

  1. Change in microbiome composition

    Evaluation of the difference in the percentage of the bacterial population before and after treatment.

    Time frame: Change from baseline microbiome composition at Day 7 and Day 14

07

Study locations

1 site
  • Centre Hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 3E4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02933918
Lead sponsor
Probionase Therapies Inc.
Responsible party
Sponsor
First posted
Oct 14, 2016
Start date
May 17, 2018
Primary completion
Dec 30, 2019
Completion
Dec 30, 2019
Last update
Nov 18, 2023

Study contacts

Martin Yvon Desrosiers, MD
study chair · Probionase Therapies Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion